BIOCRYST PHARMACEUTICALS, INC. Interest Expense Nonoperating
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Interest Expense Nonoperating of $21.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $21.71M, a 0.60% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $19.78M, a 15.81% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $14.13M, a 42.19% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $19.66M, a 20.81% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $78.87M, a 19.94% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $98.52M, a 8.98% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $108.24M, a 9.23% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $99.09M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.71M 10-Q · filed 2026-08-05 | $41.49M 10-Q · filed 2026-08-05 | $55.63M derived: sum of 3 quarters · filed 2026-08-05 | $75.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $19.78M 10-Q · filed 2026-05-06 | $33.91M derived: sum of 2 quarters · filed 2026-05-06 | $53.58M derived: sum of 3 quarters · filed 2026-05-06 | $75.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $14.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.80M derived: sum of 2 quarters · filed 2026-02-26 | $55.38M derived: sum of 3 quarters · filed 2026-08-05 | $78.87M 10-K · filed 2026-02-26 |
| 2025-09-30 | $19.66M 10-Q · filed 2025-11-04 | $41.24M derived: sum of 2 quarters · filed 2026-08-05 | $64.74M 10-Q · filed 2025-11-04 | $89.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $21.58M 10-Q · filed 2026-08-05 | $45.08M 10-Q · filed 2026-08-05 | $69.53M derived: sum of 3 quarters · filed 2026-08-05 | $94.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $23.49M 10-Q · filed 2026-05-06 | $47.94M derived: sum of 2 quarters · filed 2026-05-06 | $72.77M derived: sum of 3 quarters · filed 2026-05-06 | $97.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $24.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.28M derived: sum of 2 quarters · filed 2026-02-26 | $74.01M derived: sum of 3 quarters · filed 2026-02-26 | $98.52M 10-K · filed 2026-02-26 |
| 2024-09-30 | $24.83M 10-Q · filed 2025-11-04 | $49.56M derived: sum of 2 quarters · filed 2025-11-04 | $74.07M 10-Q · filed 2025-11-04 | $98.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $24.73M 10-Q · filed 2025-08-05 | $49.24M 10-Q · filed 2025-08-05 | $73.82M derived: sum of 3 quarters · filed 2026-02-26 | $101.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $24.51M 10-Q · filed 2025-05-06 | $49.09M derived: sum of 2 quarters · filed 2026-02-26 | $76.43M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $24.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $51.93M derived: sum of 2 quarters · filed 2026-02-26 | $108.24M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $27.34M 10-Q · filed 2024-11-05 | $83.66M 10-Q · filed 2024-11-05 | ||
| 2022-12-31 | $99.09M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |